
  
    
      
        
        As_IN the_DT HIV-_NNP 1_CD epidemic_NN continues_VBZ to_TO grow_VB ,_, mutations_NNS in_IN the_DT virus_NN that_WDT confer_VBP drug_NN
        resistance_NN are_VBP becoming_VBG increasingly_RB important_JJ in_IN the_DT clinical_JJ management_NN of_IN patients_NNS
        worldwide_NN ._. Of_IN all_PDT the_DT different_JJ virus_NN subtypes_NNS (_( A_DT ,_, B_NNP ,_, C_NNP ,_, D_NNP ,_, F_NN ,_, G_NNP ,_, H_NNP ,_, J_NNP ,_, and_CC K_NNP )_) and_CC a_DT
        rapidly_RB increasing_VBG number_NN of_IN established_VBN and_CC emerging_VBG recombinant_JJ viruses_NNS ,_, it_PRP is_VBZ subtype_NN B_NNP
        that_IN predominates_NNS in_IN Western_NNP Europe_NNP ,_, the_DT United_NNP States_NNPS ,_, and_CC the_DT rest_NN of_IN the_DT industrialized_VBN
        world_NN ._. Antiretroviral_NNP drugs_NNS were_VBD developed_VBN by_IN studying_VBG subtype_NN B_NNP ,_, and_CC most_JJS data_NNS on_IN the_DT
        genetic_JJ mechanisms_NNS of_IN HIV_NNP drug_NN resistance_NN are_VBP also_RB from_IN subtype_NN B_NNP ._. However_RB ,_, worldwide_NN ,_,
        subtype_NN B_NNP is_VBZ in_IN the_DT minority_NN (_( ~_NN 10_CD %_NN of_IN the_DT infected_JJ population_NN )_) ._. In_IN Africa_NNP ,_, for_IN example_NN ,_,
        where_WRB there_EX is_VBZ broad_JJ viral_JJ diversity_NN ,_, there_EX is_VBZ a_DT greater_JJR spread_NN of_IN subtypes_NNS ,_, with_IN subtype_NN C_NNP
        being_VBG the_DT most_RBS common_JJ ,_, representing_VBG over_IN half_NN of_IN all_DT infections_NNS ._. Although_IN it_PRP seems_VBZ that_IN
        current_JJ drugs—developed_JJ against_IN subtype_NN B_NNP virus—are_NN active_JJ against_IN non-subtype-_JJ B_NNP virus_NN ,_, one_CD
        critical_JJ issue_NN is_VBZ whether_IN viruses_NNS from_IN some_DT subtypes_NNS or_CC particular_JJ regions_NNS are_VBP more_RBR likely_JJ
        than_IN others_NNS to_TO develop_VB resistance_NN against_IN certain_JJ drugs_NNS ._. Another_DT crucial_JJ issue_NN is_VBZ to_TO
        identify_VB the_DT mutations_NNS that_WDT confer_VBP drug_NN resistance_NN in_IN non-_NN B_NNP subtypes_NNS ._. Answering_NNP these_DT
        questions_NNS might_MD determine_VB whether_IN initial_JJ treatment_NN strategies_NNS should_MD be_VB different_JJ for_IN
        people_NNS with_IN non-subtype-_JJ B_NNP viruses_NNS ,_, and_CC also_RB could_MD help_VB decide_VB how_WRB patients_NNS with_IN
        non-subtype-_JJ B_NNP virus_NN who_WP fail_VBP antiretroviral_NN therapy_NN should_MD be_VB managed_VBN ._.
        In_IN a_DT paper_NN in_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Rami_NNP Kantor_NNP and_CC colleagues_NNS from_IN a_DT worldwide_NN collaboration_NN
        have_VBP looked_VBN at_IN the_DT mutations_NNS found_VBD in_IN 3_CD ,_, 686_CD people_NNS with_IN non-subtype-_JJ B_NNP HIV-_NNP 1_CD infections_NNS
        compared_VBN with_IN those_DT in_IN 4_CD ,_, 769_CD people_NNS with_IN subtype_NN B_NNP infections_NNS ._. They_PRP wanted_VBD to_TO answer_VB two_CD
        questions_NNS :_: first_JJ ,_, whether_IN the_DT mutations_NNS that_WDT cause_VBP drug_NN resistance_NN in_IN subtype_NN B_NNP viruses_NNS
        also_RB develop_VBP in_IN non-subtype-_JJ B_NNP viruses_NNS exposed_VBN to_TO antiretroviral_NN drugs_NNS ,_, and_CC second_JJ ,_, whether_IN
        novel_NN mutations_NNS (_( i_NNP ._. e_SYM ._. ,_, not_RB previously_RB seen_VBN in_IN subtype_NN B_NNP virus_NN )_) develop_VB in_IN non-subtype-_JJ B_NNP
        viruses_NNS when_WRB they_PRP fail_VBP to_TO respond_VB to_TO antiretroviral_NN drugs_NNS ._. What_WP they_PRP found_VBD was_VBD that_IN all_DT of_IN
        the_DT 55_CD drug-resistance_JJ mutations_NNS that_WDT have_VBP been_VBN known_VBN to_TO occur_VB in_IN subtype_NN B_NNP also_RB occurred_VBD
        in_IN at_IN least_JJS one_CD non-subtype-_JJ B_NNP isolate_VB ,_, and_CC most_JJS of_IN these_DT mutations_NNS were_VBD also_RB statistically_RB
        associated_VBN with_IN antiretroviral_NN treatment_NN in_IN at_IN least_JJS one_CD non-_NN B_NNP subtype_NN ._. Conversely_RB ,_, of_IN the_DT
        67_CD mutations_NNS associated_VBN with_IN antiretroviral_NN therapy_NN in_IN at_IN least_JJS one_CD non-_NN B_NNP subtype_NN ,_, 61_CD were_VBD
        also_RB associated_VBN with_IN antiretroviral_NN therapy_NN in_IN subtype_NN B_NNP isolates_VBZ ._.
        So_IN it_PRP appears_VBZ that_IN few_JJ novel_NN mutations_NNS are_VBP arising_VBG in_IN non-subtype-_JJ B_NNP viruses_NNS exposed_VBN to_TO
        the_DT current_JJ antiretroviral_NN drugs_NNS and_CC that_IN the_DT present_JJ focus_NN on_IN subtype_NN B_NNP mutations_NNS for_IN
        global_JJ surveillance_NN and_CC genotypic_JJ assessments_NNS of_IN drug_NN resistance_NN is_VBZ a_DT reasonable_JJ approach_NN ._.
        However_RB ,_, the_DT authors_NNS emphasize_VBP that_IN differences_NNS in_IN the_DT types_NNS and_CC patterns_NNS of_IN
        drug-resistance_JJ mutations_NNS are_VBP likely_JJ to_TO differ_VB between_IN the_DT subtypes_NNS ,_, and_CC that_IN larger_JJR
        numbers_NNS of_IN samples_NNS and_CC further_JJ analyses_NNS are_VBP needed_VBN to_TO exclude_VB the_DT possibility_NN of_IN new_JJ and_CC /_NN or_CC
        rare_JJ subtype-specific_JJ mutations_NNS ._.
      
    
  
